Combined Use of Cabozantinib and Nivolumab in Clinical Practice
Introduction. The present article discusses renal cancer, one of the common malignant diseases. Historical and modern therapies are considered, including tyrosine kinase inhibitors and immune checkpoint inhibitors. The results of clinical studies evaluating the efficacy of combined drug therapy are...
Saved in:
| Main Authors: | V. E. Askarov, A. V. Sultanbaev, K. V. Menshikov, Sh. I. Musin, N. I. Sultanbaeva, E. V. Popova, I. A. Menshikova |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Bashkir State Medical University
2024-04-01
|
| Series: | Креативная хирургия и онкология |
| Subjects: | |
| Online Access: | https://www.surgonco.ru/jour/article/view/921 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Possible applications for combined lenvatinib and pembrolizumab in advanced endometrial carcinoma
by: K. V. Menshikov, et al.
Published: (2023-01-01) -
Nivolumab plus cabozantinib in metastatic renal cell carcinoma: real-world evidence from the international ARON-1 study
by: Maria T. Bourlon, et al.
Published: (2025-07-01) -
Pembrolizumab-axitinib versus nivolumab-cabozantinib as first-line therapy in patients with metastatic renal cell carcinoma: a retrospective real-world comparison (ARON-1)
by: Matteo Santoni, et al.
Published: (2025-05-01) -
The significance of therapeutic drug monitoring in detecting low medication adherence in patients with cancer: A case study of cabozantinib
by: Shinichi Maruyama, et al.
Published: (2024-09-01) -
Immune Checkpoint Inhibitors in Urothelial Carcinoma (Literature Review)
by: K. V. Menshikov, et al.
Published: (2022-10-01)